Cell Bio Human TechLtd Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Cell Bio Human TechLtd has a total shareholder equity of ₩44.1B and total debt of ₩5.8B, which brings its debt-to-equity ratio to 13.2%. Its total assets and total liabilities are ₩52.4B and ₩8.2B respectively. Cell Bio Human TechLtd's EBIT is ₩3.3B making its interest coverage ratio -419.3. It has cash and short-term investments of ₩16.8B.
Anahtar bilgiler
13.2%
Borç/özkaynak oranı
₩5.82b
Borç
| Faiz karşılama oranı | -419.3x |
| Nakit | ₩16.77b |
| Eşitlik | ₩44.13b |
| Toplam yükümlülükler | ₩8.22b |
| Toplam varlıklar | ₩52.35b |
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: A318160's short term assets (₩25.9B) exceed its short term liabilities (₩8.0B).
Uzun Vadeli Yükümlülükler: A318160's short term assets (₩25.9B) exceed its long term liabilities (₩234.5M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: A318160 has more cash than its total debt.
Borcun Azaltılması: A318160's debt to equity ratio has increased from 0.7% to 13.2% over the past 5 years.
Borç Kapsamı: A318160's debt is well covered by operating cash flow (123.6%).
Faiz Kapsamı: A318160 earns more interest than it pays, so coverage of interest payments is not a concern.